Fluphenazine decanoate

Modify Date: 2024-01-02 16:53:01

Fluphenazine decanoate Structure
Fluphenazine decanoate structure
Common Name Fluphenazine decanoate
CAS Number 5002-47-1 Molecular Weight 591.77100
Density 1.149 g/cm3 Boiling Point 658.1ºCat 760 mmHg
Molecular Formula C32H44F3N3O2S Melting Point 30-32°
MSDS N/A Flash Point 351.8ºC

 Use of Fluphenazine decanoate


Fluphenazine decanoate is a long-acting phenothiazine neuroleptic that used to treat schizophrenia. Fluphenazine decanoate is also a high and continuous dopamine D2 receptor blocker[1][2][3].

 Names

Name 2-[4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]piperazin-1-yl]ethyl decanoate
Synonym More Synonyms

 Fluphenazine decanoate Biological Activity

Description Fluphenazine decanoate is a long-acting phenothiazine neuroleptic that used to treat schizophrenia. Fluphenazine decanoate is also a high and continuous dopamine D2 receptor blocker[1][2][3].
Related Catalog
Target

Dopamine D2 receptor[2]

In Vivo Six female Persian onagers (Equus hemionus onager) are treated with Fluphenazine decanoate (0.1 mg/kg IM) or saline control. Urinary cortisol, progesterone, estrogen metabolites and behavior are monitored, and follicular dynamics are examined using ultrasonography until ovulation. Onagers demonstrate significantly lower cortisol concentrations when treated with Fluphenazine decanoate (6.61 ng/mg creatinine) compared to saline (9.73 ng/mg creatinine). There are no differences in peak estrogen or progesterone concentrations between the two groups, and all animals ovulate within the expected time frame following Fluphenazine decanoate treatment. However, some onagers exhibit only minor reductions in cortisol secretion and one treated female demonstrates a suppressed luteal progesterone peak, indicating a possible reproductive cost to Fluphenazine decanoate administration[1].
References

[1]. Wagman JD, et al. The effect of fluphenazine decanoate on glucocorticoid production, reproductive cyclicity, and the behavioral stress response in the Persian onager (Equus hemionus onager). Zoo Biol. 2015 Nov;34(6):525-34.

[2]. Uchida H, et al. Dose and dosing frequency of long-acting injectable antipsychotics: a systematic review of PET and SPECT data and clinical implications. J Clin Psychopharmacol. 2014 Dec;34(6):728-35.

[3]. Weiss RB, et al. Long-acting neuroleptic use for reproductive management of non-domestic ungulates using the domestic goat (Capra hircus) as a model. Zoo Biol. 2014 May-Jun;33(3):204-11.

 Chemical & Physical Properties

Density 1.149 g/cm3
Boiling Point 658.1ºCat 760 mmHg
Melting Point 30-32°
Molecular Formula C32H44F3N3O2S
Molecular Weight 591.77100
Flash Point 351.8ºC
Exact Mass 591.31100
PSA 61.32000
LogP 7.94050
Index of Refraction 1.537
Storage condition 2-8℃
Water Solubility Practically insoluble in water, very soluble in ethanol and in methylene chloride, freely soluble in methanol.

 Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :
HE0525000
CHEMICAL NAME :
Decanoic acid, 2-(4-(3-(2-(trifluoromethyl)phenothiazin-10-yl)propyl )- 1-piperazinyl)ethyl ester
CAS REGISTRY NUMBER :
5002-47-1
LAST UPDATED :
199612
DATA ITEMS CITED :
16
MOLECULAR FORMULA :
C32-H44-F3-N3-O2-S
MOLECULAR WEIGHT :
591.85
WISWESSER LINE NOTATION :
T C666 BN ISJ EXFFF B3- AT6N DNTJ D2OV9

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
SPECIES OBSERVED :
Human - man
DOSE/DURATION :
46 mg/kg/5Y-I
TOXIC EFFECTS :
Behavioral - muscle contraction or spasticity
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
SPECIES OBSERVED :
Human
DOSE/DURATION :
179 ug/kg
TOXIC EFFECTS :
Behavioral - antipsychotic
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
21 mg/kg/6D-I
TOXIC EFFECTS :
Cardiac - pulse rate Gastrointestinal - changes in structure or function of salivary glands Nutritional and Gross Metabolic - body temperature decrease
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
SPECIES OBSERVED :
Human - man
DOSE/DURATION :
1071 ug/kg/12D-I
TOXIC EFFECTS :
Behavioral - ataxia Lungs, Thorax, or Respiration - dyspnea Skin and Appendages - sweating
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
19 mg/kg
TOXIC EFFECTS :
Sense Organs and Special Senses (Eye) - effect, not otherwise specified Lungs, Thorax, or Respiration - respiratory depression Nutritional and Gross Metabolic - body temperature decrease
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intramuscular
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
576 mg/kg
TOXIC EFFECTS :
Sense Organs and Special Senses (Eye) - effect, not otherwise specified Behavioral - altered sleep time (including change in righting reflex) Skin and Appendages - hair
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intramuscular
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
60 mg/kg
TOXIC EFFECTS :
Sense Organs and Special Senses (Eye) - effect, not otherwise specified Behavioral - altered sleep time (including change in righting reflex) Skin and Appendages - hair
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
46 mg/kg/52W-I
TOXIC EFFECTS :
Liver - changes in liver weight Kidney, Ureter, Bladder - other changes in urine composition Nutritional and Gross Metabolic - weight loss or decreased weight gain
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
82 mg/kg/52W-I
TOXIC EFFECTS :
Blood - normocytic anemia Blood - changes in bone marrow (not otherwise specified) Related to Chronic Data - changes in prostate weight
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
DOSE :
230 mg/kg
SEX/DURATION :
male 4 week(s) pre-mating female 2 week(s) pre-mating female 1-7 day(s) after conception
TOXIC EFFECTS :
Reproductive - Maternal Effects - menstrual cycle changes or disorders
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
DOSE :
5 mg/kg
SEX/DURATION :
female 17 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - stillbirth Reproductive - Effects on Newborn - viability index (e.g., # alive at day 4 per # born alive) Reproductive - Effects on Newborn - weaning or lactation index (e.g., # alive at weaning per # alive at day 4)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
DOSE :
25 mg/kg
SEX/DURATION :
female 17 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea) Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain) Reproductive - Effects on Newborn - delayed effects
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
DOSE :
5 mg/kg
SEX/DURATION :
female 7 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - sex ratio

MUTATION DATA

TEST SYSTEM :
Rodent - rat
DOSE/DURATION :
20 mg/kg/12W (Intermittent)
REFERENCE :
MUREAV Mutation Research. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1964- Volume(issue)/page/year: 244,331,1990 *** REVIEWS *** TOXICOLOGY REVIEW ABPYBL Advances in Biochemical Psychopharmacology. (Raven Press, 1185 Ave. of the Americas, New York, NY 10036) V.1- 1969- Volume(issue)/page/year: 9,301,1974 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X5576 No. of Facilities: 16 (estimated) No. of Industries: 1 No. of Occupations: 2 No. of Employees: 794 (estimated) No. of Female Employees: 419 (estimated)

 Safety Information

Hazard Codes Xn
RIDADR UN 3249
RTECS HE0525000
Packaging Group II
Hazard Class 6.1(a)
HS Code 3003909090

 Customs

HS Code 3003909090

 Articles26

More Articles
Adherence challenges and long-acting injectable antipsychotic treatment in patients with schizophrenia.

J. Psychosoc. Nurs. Ment. Health Serv. 51(3) , 13-8, (2013)

Medication nonadherence has been associated with persistence of psychotic symptoms, relapse, and hospitalization in patients with schizophrenia. Patients with untreated psychosis are significantly les...

Ten year outcomes of outpatients with schizophrenia on conventional depot antipsychotics: a systematic chart review.

Int. Clin. Psychopharmacol. 28(5) , 261-6, (2013)

Long-term follow-up data of patients with schizophrenia on depot antipsychotics have been few and the longest follow-up period has been up to 7 years. We carried out a systematic chart review to exami...

Differing effects of antipsychotic medications on substance abuse treatment patients with co-occurring psychotic and substance abuse disorders.

Am. J. Addict. 15(2) , 166-73, (2006)

This retrospective study of patients treated in a ninety-day, inpatient, dual-diagnosis treatment program examined antipsychotic effectiveness in this population using length of stay in treatment and ...

 Synonyms

Fluphenazine depot
1-decanoyloxy-2-{4-[3-(2-trifluoromethyl-phenothiazin-10-yl)-propyl]-piperazin-1-yl}-ethane
Modecate
Fluphenaline decanoate
Fluphenazindecanoat
Moditen-depo
Fluorophenazine decanoate
Dapotum D
Fluphenazine decanoate
fluphenazine O-decanoate
Flufenazine decanoate
Fluphenazindecanat
Moditen depot
Top Suppliers:I want be here




Get all suppliers and price by the below link:

Fluphenazine decanoate suppliers

Fluphenazine decanoate price